Professor Andrea Varrone at Karolinska Institutet has secured a significant grant of over USD 1.4 million from the Michael J. Fox Foundation for Parkinson’s Research. This funding will support a pivotal study aimed at enhancing understanding of Parkinson’s disease by evaluating a new tracer that reveals crucial brain activity as the disease progresses.
In his role as a professor of molecular PET (positron emission tomography) and principal investigator at the Department of Clinical Neuroscience, Professor Varrone employs a PET technique to investigate how neurodegenerative diseases, notably Parkinson’s, impact the brain. The method involves administering a radioactively labelled tracer known as a radioligand, which binds to specific targets in the brain, allowing researchers to visualize various biological processes.
Innovative Tracer to Enhance Understanding of Parkinson’s
The tracer being studied, [11 C]UCB-1A, was developed by Professor Varrone and his team. It is designed to visualize the synapses that connect cerebral neurons. “Given that synapses are lost during Parkinson’s disease, our tracer has enormous potential when it comes to increasing our understanding of the disease mechanisms and judging if new treatments can retard this loss,” says Professor Varrone.
The current study, funded by the Michael J. Fox Foundation, will involve both healthy participants and individuals diagnosed with Parkinson’s disease. If successful, it could lead to the development of a new diagnostic tool. Professor Varrone emphasizes that the results could enable earlier diagnosis, enhance the evaluation of new therapies, and contribute to more effective, personalized care.
The research environment at Karolinska Institutet, along with advanced imaging core facilities in Bioclinicum, provides essential infrastructure for the research team. The strategic location near Nya Karolinska Hospital fosters close collaboration between preclinical and clinical research, essential for translating discoveries into patient benefits rapidly.
Potential Impact on Parkinson’s Disease Treatment
Professor Varrone hopes that the study will demonstrate the reliability of [11 C]UCB-1A for clinical use. “Our aim is for the tracer to be used as a diagnostic tool and as a means for monitoring the effects of new therapies,” he states. If the method is validated, it could become an integral part of the ongoing fight against Parkinson’s disease.
Founded by actor Michael J. Fox, who himself has been diagnosed with Parkinson’s disease, the Michael J. Fox Foundation is recognized as the world’s largest private organization dedicated to Parkinson’s research. The foundation has previously funded numerous projects at Karolinska Institutet, underscoring its commitment to advancing research in this critical field. In 2010, Michael J. Fox received an honorary doctorate from the institute, reflecting his significant contributions to Parkinson’s research initiatives.
This grant represents a promising step forward in the quest for better diagnostic and therapeutic options for those affected by Parkinson’s disease, potentially leading to more personalized and effective care strategies in the future.
